Business
Currency:USD
2024/FY
Stock NameRevenueRatio
BRUKINSA®2.64B69.40%
Tislelizumab620.84M16.29%
XGEVA®224.4M5.89%
BLINCYTO®74.33M1.95%
KYPROLIS®66.17M1.74%
Other60.04M1.58%
POBEVCY®53.51M1.40%
REVLIMID®36.03M0.95%
Collaboration revenue30.7M0.81%
View all
Region
Currency:USD
2024/FY
Stock NameRevenueRatio
U.S.1.96B51.37%
China1.41B37.04%
Europe362.63M9.52%
Rest of world78.81M2.07%